Inflammation in chronic obstructive pulmonary disease (COPD) is often corticosteroid resistant and, thus, alternative anti-inflammatory approaches are needed. Since it is still not clear whether blocking specific pro-inflammatory factors may provide clinical benefit in COPD, we have performed a meta-analysis to quantify the impact of monoclonal antibodies (mABs) targeting the cytokine/chemokine-mediated inflammation in COPD. A pairwise and network meta-analyses were performed by extracting data from randomized clicnial trials on COPD concerning the impact of mABs vs. placebo on the risk of exacerbation, forced expiratory volume in 1 s (FEV1), and St. George's Respiratory Questionnaire (SGRQ). Data on the interleukin (IL)-1β antagonist canakinumab, IL-1R1 antagonist MEDI8986, IL-5 antagonist mepolizumab, IL-5R antagonist benralizumab, IL-8 antagonist ABX-IL8, and TNF-α antagonist infliximab were found. Overall, mAB therapy had a moderate impact on the risk exacerbation, but not on FEV1and SGRQ. The pairwise meta-analysis performed in eosinophilic patients, and the network approach, indicated that mepolizumab elicited a beneficial effect against the risk of exacerbation, whereas benralizumab was more effective in improving both FEV1and SGRQ. This study demonstrates that targeting the pathway activated by IL-5 may have a beneficial impact in eosinophilic COPD patients.
Emerging biological therapies for treating chronic obstructive pulmonary disease : a pairwise and network meta-analysis / P. Rogliani, M.G. Matera, E. Puxeddu, M. Mantero, F. Blasi, M. Cazzola, L. Calzetta. - In: PULMONARY PHARMACOLOGY & THERAPEUTICS. - ISSN 1094-5539. - 50(2018), pp. 28-37.
|Titolo:||Emerging biological therapies for treating chronic obstructive pulmonary disease : a pairwise and network meta-analysis|
|Parole Chiave:||Benralizumab; COPD; Mepolizumab; Meta-analysis; Monoclonal antibodies; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)|
|Settore Scientifico Disciplinare:||Settore MED/10 - Malattie dell'Apparato Respiratorio|
|Data di pubblicazione:||2018|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.pupt.2018.03.004|
|Appare nelle tipologie:||01 - Articolo su periodico|
File in questo prodotto:
|emerging biological therapies for treating COPD Pulmonary Pharmacology Therapeutics 2018.pdf||Publisher's version/PDF||Administrator Richiedi una copia|